The role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours

• Published in: Journal of cancer research and clinical oncology Vol. 149; no. 11; pp. 8379 - 8391
• Main Authors: Hannon Barroeta, Patricia, O’Sullivan, Maureen J., Zisterer, Daniela M.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2023; Springer Nature B.V
• Subjects: Acetylcysteine; antioxidant activity; Antioxidants; Antioxidants - pharmacology; Apoptosis; Buthionine Sulfoximine; Cancer Research; Cancer therapies; cancer therapy; Cell Line, Tumor; Central nervous system; Chemoresistance; Chemotherapy; Child; childhood; Children; Cisplatin; Cisplatin - pharmacology; drug therapy; Glutathione; Glutathione - metabolism; Hematology; Humans; Internal Medicine; Malignancy; Medicine; Medicine & Public Health; neoplasms; NF-E2-Related Factor 2 - metabolism; Oncology; Oxidative stress; prognosis; Reactive oxygen species; Reactive Oxygen Species - metabolism; Rhabdoid Tumor - drug therapy; siRNA; transcription factors; Tumors; Reactive oxygen species; Nuclear erythroid-related factor-2; Malignant rhabdoid tumour; Chemoresistance; Apoptosis; Glutathione

Purpose Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is a major issue in the treatment of this malignancy leading to an urgent need for a greater understa...